Literature DB >> 27291925

Neurodevelopmental Outcomes in Children with PHACE Syndrome.

Cheryl L Brosig1, Dawn H Siegel1,2, Anita N Haggstrom3,4, Ilona J Frieden5,6, Beth A Drolet1,2.   

Abstract

BACKGROUND: Practitioners who work with children with posterior fossa, facial hemangiomas, arterial anomalies, cardiovascular anomalies, and abnormalities of the eye (PHACE) syndrome need information about neurodevelopmental outcomes to provide appropriate anticipatory guidance and education for parents. This study aimed to determine the neurodevelopmental outcomes in children with PHACE syndrome and identify which children may be at greatest risk for delays.
METHODS: Children with a diagnosis of PHACE syndrome (ages 4-18 yrs) were recruited from the PHACE Syndrome International Clinical Registry and Genetic Repository. Participants (n = 25) underwent a neurodevelopmental evaluation at a children's hospital tertiary care referral center between 2009 and 2013. Children completed standardized neurocognitive tests assessing multiple domains. Parents completed standardized questionnaires assessing behavioral and emotional functioning.
RESULTS: Results were analyzed according to cohort and individual subject. Mean scores for the cohort did not differ significantly from test norms in most domains. The only subtest that the cohort scored lower on than test norms was Word Structure, a language task. Forty-four percent of the sample scored within the normal range in all domains, 28% had one score in the at-risk range (1-2 standard deviations [SDs] below the mean), 12% had two or more scores in the at-risk range, and 16% had at least one score in the impaired range (>2 SDs below the mean).
CONCLUSION: Although most children in this cohort of patients with PHACE syndrome did not have significant neurodevelopmental deficits, a subset of patients had delays in multiple areas. Practitioners who work with these children should routinely ask about neurocognitive and developmental skills. Children with more severe phenotypes should be referred for appropriate evaluations and intervention services.
© 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2016        PMID: 27291925     DOI: 10.1111/pde.12870

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  6 in total

1.  Asymmetric Meckel Cave Enlargement: A Potential Marker of PHACES Syndrome.

Authors:  J N Wright; V Wycoco
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-13       Impact factor: 3.825

2.  Structural malformations of the brain, eye, and pituitary gland in PHACE syndrome.

Authors:  Jack E Steiner; Garrett N McCoy; Christopher P Hess; William B Dobyns; Denise W Metry; Beth A Drolet; Mohit Maheshwari; Dawn H Siegel
Journal:  Am J Med Genet A       Date:  2017-11-24       Impact factor: 2.802

3.  Prenatal Risk Factors for PHACE Syndrome: A Study Using the PHACE Syndrome International Clinical Registry and Genetic Repository.

Authors:  Joy Wan; Jack Steiner; Eulalia Baselga; Francine Blei; Maria Cordisco; Maria C Garzon; Deborah S Goddard; Anita Haggstrom; Alfons Krol; Ilona J Frieden; Denise Metry; Kimberly D Morel; Judith M A Verhagen; Orli Wargon; Beth A Drolet; Dawn H Siegel
Journal:  J Pediatr       Date:  2017-09-01       Impact factor: 4.406

Review 4.  PHACE syndrome: clinical manifestations, diagnostic criteria, and management.

Authors:  Anita Rotter; Luciana Paula Samorano; Maria Cecília Rivitti-Machado; Zilda Najjar Prado Oliveira; Bernardo Gontijo
Journal:  An Bras Dermatol       Date:  2018-06       Impact factor: 1.896

5.  Behavioral problems of Mandarin-speaking late-talking toddlers and preschool aged children: A prospective case-control study in Taiwan.

Authors:  Hsin-Hui Lu; Feng-Ming Tsao; Jeng-Dau Tsai
Journal:  Medicine (Baltimore)       Date:  2020-11-25       Impact factor: 1.889

6.  Association of Demographic Factors and Infantile Hemangioma Characteristics With Risk of PHACE Syndrome.

Authors:  Colleen H Cotton; Jusleen Ahluwalia; Daniel M Balkin; Ilona J Frieden; Anita N Haggstrom; Leslie A Castelo-Soccio; Carmen Liy-Wong; Elena Pope; Jack E Steiner; Dawn H Siegel; Esteban Fernandez-Faith; Kimberly D Morel; Christine T Lauren; Maria C Garzon; Anthony J Mancini; Sarah L Chamlin; Megha M Tollefson; Marilyn G Liang; Sophia Delano; Sharon A Glick; Marcia Hogeling; Victoria R Barrio
Journal:  JAMA Dermatol       Date:  2021-06-16       Impact factor: 11.816

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.